SLC2A1 and neoplasm: Building upon our findings that GLUT1 inhibition promotes the accumulation of CD8+ T cells in the tumor mass, we hypothesized that combining GLUT1 inhibition with doxorubicin could impede tumor growth by enhancing the anti-tumor function of cytotoxic T cells.